Drug Type Tumor necrosis factors |
Synonyms ARENEGYR, CNGRC peptide-TNF alpha conjugate, NGR-HTNF + [5] |
Target |
Mechanism APN modulators(Aminopeptidase N modulators), TNFR modulators(Tumor necrosis factor receptor modulators), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Tengonermin | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mesothelioma | NDA/BLA | EU | - | |
Malignant Pleural Mesothelioma | Phase 3 | US | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | BE | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | CA | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | EG | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | FR | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | IE | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | IT | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | NL | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | PL | 12 Apr 2010 |
Phase 2 | 28 | ojavqzlavg(kfshabarmy) = babrjtgymj ajjimjaioi (qytcpthjyb, rmvnxbsvgf - eddjtggbla) View more | - | 04 Oct 2019 | |||
Phase 3 | 400 | (A: NGR-hTNF + BIC) | hafgfjzohx(yunwfrkgco) = uxyjpwclxi lxidfddbpy (cthmyhmlbl, ehwoihveie - itgcpomfhh) View more | - | 17 Sep 2019 | ||
Placebo plus Best Investigator's Choice (BIC) (B: Placebo+BIC) | hafgfjzohx(yunwfrkgco) = qorcmdguti lxidfddbpy (cthmyhmlbl, okocihjqhg - sbohfwxgck) View more | ||||||
Phase 2 | 28 | NGR-hTNF/RCHOP | dqybfydfpg(btesovqxif) = uzaobqcsux kjhassoolf (lynfxqgdqr, 59 - 91) View more | Positive | 12 Jun 2019 | ||
Phase 3 | Malignant Pleural Mesothelioma Second line | 400 | gemcitabine+vinorelbine+doxorubicin+NGR-hTNF | unnhkecajv(lednomzhrp) = cvwzjwzefs wtxmlftsxu (zfavsoosfy, 29 - 50) View more | Positive | 03 Jun 2018 | |
gemcitabine+vinorelbine+doxorubicin+placebo | unnhkecajv(lednomzhrp) = onmpvlaqdx wtxmlftsxu (zfavsoosfy, 16 - 32) View more | ||||||
Phase 3 | 400 | btqjkgemwu(ushwdonytl) = hbdyqyeyjq uweectnopw (hfiwvkhzrm ) View more | Positive | 20 May 2016 | |||
Placebo plus BIC | btqjkgemwu(ushwdonytl) = duutcfmwqk uweectnopw (hfiwvkhzrm ) View more | ||||||
Phase 3 | Malignant Pleural Mesothelioma First line | 400 | ycdkebilda(dpxcbgtuxg) = ngbmsbobjw dyjqikozym (rwtvbwzkxa, 4.2 - 5.1) | Positive | 20 May 2015 | ||
Phase 3 | 400 | ritqyijqop(juvfrjzkwf) = qaljgczmhm onylnotoos (opzukgsbtt ) View more | Negative | 20 May 2015 | |||
Placebo plus best investigator choice (BIC) | ritqyijqop(juvfrjzkwf) = aeozvhbwyk onylnotoos (opzukgsbtt ) View more | ||||||
Phase 2 | 69 | rycxgneibx(aybinytjtj) = iaucrkoypy fmxevvahvw (hmnbtokguc ) | - | 20 May 2014 | |||
rycxgneibx(aybinytjtj) = elohvovfsv fmxevvahvw (hmnbtokguc ) | |||||||
Phase 2 | 66 | NGR-hTNF (LD) | jzparvmiyc(wrhsqprghl) = kpwvbgymrm oqcyqkjilg (kfycybmmbv, 1.1 - 1.5) | - | 20 May 2013 | ||
jzparvmiyc(wrhsqprghl) = zyhbnfmydy oqcyqkjilg (kfycybmmbv, 1.1 - 1.8) | |||||||
Phase 2 | 396 | NGR-hTNF + CT | ayigeblewj(nafryrxszv) = ulpbfctisd ufjayywmct (nafmymbioh ) View more | - | 20 May 2013 | ||
- |